<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354092</url>
  </required_header>
  <id_info>
    <org_study_id>141593</org_study_id>
    <nct_id>NCT02354092</nct_id>
  </id_info>
  <brief_title>Paracervical Block for Pain Control With Osmotic Dilator Placement</brief_title>
  <official_title>Paracervical Block for Pain Control During Osmotic Dilator Placement: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Planned Parenthood Federation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical dilators are frequently used for preparation prior to second trimester surgical
      abortion. While their use decreases complications associated with surgical abortion, their
      placement is often uncomfortable for the patient. Currently there are no proven methods for
      reducing pain during osmotic dilator placement. The use of numbing medication around the
      cervix (paracervical block) may decrease this placement pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is estimated that 1.21 million abortions were performed in 2008. Of these, approximately
      11% occurred in the second trimester and 1.4% occurred after 21 weeks gestation. In the
      United States, dilation and evacuation (D&amp;E) is the most common method of terminating a
      second trimester pregnancy with greater than 98% of second trimester abortions occurring by
      D&amp;E.

      Pre-procedure cervical preparation decreases the incidence of complications associated with
      D&amp;E. Cervical dilators are often used prior to second trimester D&amp;Es to aid in softening and
      dilating the cervix. Typically, dilator placement occurs the day of the D&amp;E or 1-2 days prior
      and oftentimes occurs in an outpatient clinic setting without anesthesia readily available.
      Many women experience moderate to severe discomfort with osmotic dilator insertion. Providers
      use various methods to minimize this discomfort including paracervical block (PCB),
      non-steroidal anti-inflammatory medications (NSAIDs), anxiolytics and narcotics. In
      particular, PCB and NSAIDs are readily available in the clinic setting and can be used for
      this purpose. There is, however, no data to support their efficacy in ameliorating the pain
      of dilator insertion.

      Paracervical blocks are used commonly to decrease pain in abortion procedures and other
      gynecological procedures. The PCB is thought to work primarily by blocking pain conduction
      via Frankenhauser's plexus. As such, their effect may be most important in relieving the pain
      associated with cervical dilation. In a recent randomized control trial, PCB prior to first
      trimester surgical abortion was found to significantly reduce pain with cervical dilation and
      uterine aspiration. Since osmotic dilator placement primarily involves cervical manipulation
      and dilation, PCB may provide some pain relief over placebo. The research team proposes a
      randomized controlled trial to evaluate the efficacy of a PCB in decreasing pain associated
      with osmotic dilator placement. This trial will also provide information about the degree of
      pain that women experience during osmotic dilator placement; information not previously
      known.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 2, 2015</start_date>
  <completion_date type="Actual">August 25, 2015</completion_date>
  <primary_completion_date type="Actual">August 25, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at Time of Osmotic Dilator Placement</measure>
    <time_frame>Within 5 minutes of PCB or sham procedure</time_frame>
    <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain With Paracervical Block or Sham</measure>
    <time_frame>Within 5 minutes after baseline</time_frame>
    <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Pain at Baseline</measure>
    <time_frame>Baseline, just prior to PCB or sham procedure</time_frame>
    <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain With Overall Dilator Placement</measure>
    <time_frame>15 minutes after dilator placement</time_frame>
    <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Abortion Late</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Sham Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracervical Block Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local anesthetic for tenaculum placement</intervention_name>
    <description>2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate</description>
    <arm_group_label>Paracervical Block Group</arm_group_label>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions</description>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paracervical Block</intervention_name>
    <description>18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate</description>
    <arm_group_label>Paracervical Block Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dilator Placement</intervention_name>
    <description>Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference
Drugs:
Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.
Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.</description>
    <arm_group_label>Paracervical Block Group</arm_group_label>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Post-procedural assessment</intervention_name>
    <description>15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.</description>
    <arm_group_label>Paracervical Block Group</arm_group_label>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preprocedural pain control</intervention_name>
    <description>800 mg Ibuprofen taken before dilator placement</description>
    <arm_group_label>Paracervical Block Group</arm_group_label>
    <arm_group_label>Sham Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  voluntarily seeking surgical pregnancy termination

          -  gestational age on day of study 14w0d to 23w6d confirmed by pelvic ultrasound with a
             viable pregnancy (no fetal demise diagnosed)

          -  eligible for second trimester D&amp;E

          -  having osmotic dilators placed for cervical preparation the day prior to D&amp;E

          -  able and willing to give informed consent and agree to terms of the study

          -  able to speak and read English or Spanish

        Exclusion Criteria:

          -  took any prescription or illegal drugs 24 hours prior to the appointment

          -  drank alcohol 12 hours prior to the appointment

          -  took any over the counter pain medications 12 hours prior to the appointment other
             than the standard 800mg of Ibuprofen

          -  contraindications to osmotic dilators

          -  allergic reaction or hypersensitivity to NSAIDs or lidocaine

          -  untreated acute cervicitis or pelvic inflammatory disease

          -  weight &lt;100 pounds
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Bayer, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Department of Reproductive Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheila Mody, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Department of Reproductive Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelly Culwell, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood of the Pacific Southwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of the Pacific Southwest: First Avenue Family Planning Michelle Wagner Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Offices South: Women's Health Services</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glantz JC, Shomento S. Comparison of paracervical block techniques during first trimester pregnancy termination. Int J Gynaecol Obstet. 2001 Feb;72(2):171-8.</citation>
    <PMID>11166751</PMID>
  </reference>
  <reference>
    <citation>Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003 Sep;4(7):407-14.</citation>
    <PMID>14622683</PMID>
  </reference>
  <reference>
    <citation>Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health. 2008 Mar;40(1):6-16. doi: 10.1363/4000608.</citation>
    <PMID>18318867</PMID>
  </reference>
  <reference>
    <citation>Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol. 1983 Aug;62(2):185-90.</citation>
    <PMID>6866362</PMID>
  </reference>
  <reference>
    <citation>Cansino C, Edelman A, Burke A, Jamshidi R. Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1220-6. doi: 10.1097/AOG.0b013e3181c1a55b.</citation>
    <PMID>19935022</PMID>
  </reference>
  <reference>
    <citation>Rowbotham MC. What is a &quot;clinically meaningful&quot; reduction in pain? Pain. 2001 Nov;94(2):131-2. Review.</citation>
    <PMID>11690725</PMID>
  </reference>
  <reference>
    <citation>Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983 May 28;1(8335):1182-5.</citation>
    <PMID>6133988</PMID>
  </reference>
  <reference>
    <citation>Strauss LT, Gamble SB, Parker WY, Cook DA, Zane SB, Hamdan S; Centers for Disease Control and Prevention. Abortion surveillance--United States, 2003. MMWR Surveill Summ. 2006 Nov 24;55(11):1-32.</citation>
    <PMID>17119534</PMID>
  </reference>
  <reference>
    <citation>Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996 Apr;27(4):485-9.</citation>
    <PMID>8604867</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>September 24, 2018</results_first_submitted>
  <results_first_submitted_qc>May 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2019</results_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Lisa Bayer</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cervical dilation</keyword>
  <keyword>pain</keyword>
  <keyword>paracervical block</keyword>
  <keyword>osmotic dilators</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sham Group</title>
          <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
        <group group_id="P2">
          <title>Paracervical Block Group</title>
          <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham Group</title>
          <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
        <group group_id="B2">
          <title>Paracervical Block Group</title>
          <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.0" spread="4.3"/>
                    <measurement group_id="B2" value="27.6" spread="7.2"/>
                    <measurement group_id="B3" value="25.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain at Time of Osmotic Dilator Placement</title>
        <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
        <time_frame>Within 5 minutes of PCB or sham procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Group</title>
            <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
          <group group_id="O2">
            <title>Paracervical Block Group</title>
            <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Pain at Time of Osmotic Dilator Placement</title>
          <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="37"/>
                    <measurement group_id="O2" value="32" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain With Paracervical Block or Sham</title>
        <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
        <time_frame>Within 5 minutes after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Group</title>
            <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
          <group group_id="O2">
            <title>Paracervical Block Group</title>
            <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Pain With Paracervical Block or Sham</title>
          <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="21"/>
                    <measurement group_id="O2" value="39" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Pain at Baseline</title>
        <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
        <time_frame>Baseline, just prior to PCB or sham procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Group</title>
            <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
          <group group_id="O2">
            <title>Paracervical Block Group</title>
            <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Pain at Baseline</title>
          <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4"/>
                    <measurement group_id="O2" value="19" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain With Overall Dilator Placement</title>
        <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point.</description>
        <time_frame>15 minutes after dilator placement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sham Group</title>
            <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
          <group group_id="O2">
            <title>Paracervical Block Group</title>
            <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Pain With Overall Dilator Placement</title>
          <description>Measure of distance (mm) from the left (&quot;no pain&quot;) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="30"/>
                    <measurement group_id="O2" value="35" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sham Group</title>
          <description>This non-intervention group will receive the sham paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
Sham Paracervical Block done with capped spinal needle
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
        <group group_id="E2">
          <title>Paracervical Block Group</title>
          <description>This intervention group will receive the paracervical block. This intervention will include
Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement
Local anesthetic for tenaculum placement
18 ml 1% buffered lidocaine Paracervical Block
osmotic dilators placed in the usual fashion
postprocedural assessment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ob/Gyn Regulatory Specialist, Women's Health Research Unit</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-3666</phone>
      <email>whru@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

